7月19日消息 - 环球医学据悉，联合国艾滋病规划署（UNAIDs）对美国允许使用阻止HIV的药物的决定表示欢迎。

UNAIDs在从其总部日内瓦发表的一份声明说，该药将被用于“防止未感染HIV但有暴露于病毒的高风险的人群的HIV性传播”。

该机构说，自2004年以来，该药丸中的药物组合——恩曲他滨和替诺福韦酯富马酸——已被用于帮助HIV感染者，但却不能防止感染。

UNAIDS说，美国食品和药物管理局（FDA）基于临床试验结果于周一批准了该药（名为Truvada），试验结果发现，每天口服替诺福韦或恩曲他滨/富马酸替诺福韦酯，可带来显著的预防益处。

这种HIV预防法被称为暴露前预防（PrEP），其作为更广泛的HIV预防策略（包括使用避孕套和其他更为安全的性行为，减少风险的辅导和控制其他性传播感染）的一部分而获FDA批准。（环球医学）

原文：

UNAIDS Welcomes US Approval of HIV Prevention Pill

UNAIDS welcomes the decision by the United States to allow the use of a drug to stop HIV. 

The pill will be used "to prevent the sexual transmission of HIV for people who do not have HIV, but who are at high risk of being exposed to the virus", UNAIDS said in a statement from its Geneva headquarters. 

Since 2004, the combination of drugs contained in the pill -- emtricitabine and tenofovir disoproxil fumarate -- has been used to help those with HIV, but not to protect against infection, the agency said. 

The US Food and Drug Administration (FDA) approved the pill -- known as Truvada -- on Monday based on results from clinical trials which found that a daily oral dose of tenofovir, or emtricitabine/tenofovir disoproxil fumarate, carried significant preventative benefits, UNAIDS said. 

HIV prevention of this kind is called pre-exposure prophylaxis, or PrEP, which the FDA approved as part of a wider HIV prevention strategy that includes condom use and other safer sex practices, risk reduction counselling and control of other sexually transmitted infections.
 

相关链接：http://www.medindia.net/news/unaids-welcomes-us-approval-of-hiv-prevention-pill-104245-1.htmhttp://www.medindia.net/news/fda-delays-approval-of-clot-busting-drug-103263-1.htmhttp://www.medindia.net/news/fda-delays-approval-of-clot-busting-drug-103263-1.htmhttp://www.medindia.net/news/fda-delays-approval-of-clot-busting-drug-103263-1.htmhttp://www.medindia.net/news/fda-delays-approval-of-clot-busting-drug-103263-1.htm126.am

版权声明：本文系环球医学独家稿件，版权为环球医学所有。欢迎转载，请务必注明出处（环球医学网），否则必将追究法律责任。